-
11.发明申请公开(公告)号：US20220144629A1
公开(公告)日：2022-05-12
申请号：US17096738
申请日：2020-11-12
Applicant: Trevor Percival Castor , Vasudevacharya Jayarama , James A. McSwiggen
Inventor： Trevor Percival Castor , Vasudevacharya Jayarama , James A. McSwiggen
IPC: B82Y5/00 , C12N15/113 , B82Y40/00 , C07K14/54
Abstract: The present invention pertains to the nanoencapsulation of siRNA and other biologics in phospholipid nanosomes for the improved delivery of siRNA and other biologics to targeted diseased human or animal organs and human or animal cells and apparatus and methods for making the same. In embodiments of the present invention, novel siRNAs were designed to down regulate CCR5 and CD4, based on an analysis of all known alternative transcripts for each gene from both human and monkey (Macaca mulatta) genomes. Embodiments of the present invention feature supercritical, critical and near critical fluids. Embodiments of the present invention also pertain to down regulation of CXCR4 receptor and targeting of nanosomes containing specific siRNA sequences to cells expressing those receptors on the cell surface by coating them with specific ligands. These include ligands for the receptors CCR5, CD4 and CXCR4.
-
12.发明申请公开(公告)号：US20220142934A1
公开(公告)日：2022-05-12
申请号：US17092257
申请日：2020-11-07
Applicant: Trevor Percival Castor
Inventor： Trevor Percival Castor
IPC: A61K9/51 , A61K31/365 , A61K31/203 , A61K9/00 , A61J3/07 , A61P25/28
Abstract: Embodiments of the present invention are directed to the administration of co-encapsulated bryostatins and retinoids for the treatment of disease, wherein the co-encapsulated bryostatins and retinoids synergistically increase expression of alpha secretase activity in patients. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and ophthalmic diseases such as glaucoma.
-
公开(公告)号：US6051694A
公开(公告)日：2000-04-18
申请号：US156197
申请日：1998-09-17
Applicant: Trevor Percival Castor , Glenn Thomas Hong
Inventor： Trevor Percival Castor , Glenn Thomas Hong
CPC classification number: C12N9/98 , C07K1/36 , A61K38/00 , Y02P20/544
Abstract: Liquefied gases, compressed gases, and supercritical fluids are used to form protein particles without first dissolving the protein. The product material is expected to retain full activity and be devoid of residual processing chemicals such as solvents, salts, or surfactants.
Abstract translation: 使用液化气体，压缩气体和超临界流体来形成蛋白质颗粒，而不首先溶解蛋白质。 产品材料预期保持完全的活性，并且不含残留的加工化学品如溶剂，盐或表面活性剂。
-
公开(公告)号：US20240366818A1
公开(公告)日：2024-11-07
申请号：US18031603
申请日：2021-10-12
Applicant: Trevor Percival Castor
Inventor： Trevor Percival Castor
IPC: A61L2/00
Abstract: The present invention is a physical pathogen reduction method and apparatus for controlling or eliminating transfusion-transmittable infections. This purely physical technique does not involve the use of heat, chemicals and/or irradiation, each of which has significant drawbacks in the pathogen reduction of human plasma. The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in units of human plasma, while retaining the natural biological activity. integrity and potency of the treated plasma. The method uses critical, near-critical or supercritical fluids for viral and pathogen reduction of units of donor blood plasma, using novel blood plasma bags. The apparatus is in the form of a bench-top or mobile transportable unit, which can be used in hospitals, blood banks, medical facilities and hot zones in developing countries for the clearance of viruses from human plasma.
-
15.发明授权公开(公告)号：US11981714B2
公开(公告)日：2024-05-14
申请号：US17096738
申请日：2020-11-12
Applicant: Trevor Percival Castor , Vasudevacharya Jayarama , James A McSwiggen
Inventor： Trevor Percival Castor , Vasudevacharya Jayarama , James A McSwiggen
IPC: C07K14/54 , B82Y5/00 , B82Y40/00 , C12N15/113
CPC classification number: C07K14/5446 , B82Y5/00 , B82Y40/00 , C12N15/113
Abstract: The present invention pertains to the nanoencapsulation of siRNA and other biologics in phospholipid nanosomes for the improved delivery of siRNA and other biologics to targeted diseased human or animal organs and human or animal cells and apparatus and methods for making the same. In embodiments of the present invention, novel siRNAs were designed to down regulate CCR5 and CD4, based on an analysis of all known alternative transcripts for each gene from both human and monkey (Macaca mulatta) genomes. Embodiments of the present invention feature supercritical, critical and near critical fluids. Embodiments of the present invention also pertain to down regulation of CXCR4 receptor and targeting of nanosomes containing specific siRNA sequences to cells expressing those receptors on the cell surface by coating them with specific ligands. These include ligands for the receptors CCR5, CD4 and CXCR4.
-
Patent Agency Ranking
公开(公告)号：US20230250107A1
公开(公告)日：2023-08-10
申请号：US18130391
申请日：2023-04-03
Applicant: Trevor Percival Castor
Inventor： Trevor Percival Castor
IPC: C07D493/22 , A61K31/365
CPC classification number: C07D493/22 , A61K31/365
Abstract: Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.
-
公开(公告)号：US20220296522A1
公开(公告)日：2022-09-22
申请号：US17359617
申请日：2021-06-27
Applicant: Trevor Percival Castor
Inventor： Trevor Percival Castor
IPC: A61K9/16 , A61K9/00 , A61K31/366 , A61P25/28
Abstract: Embodiments of the present invention are directed to drug delivery systems, dosage forms and methods for the intranasal administration of Bryostatins for the treatment of neuro-degenerative diseases. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down syndrome and Alzheimer's disease.
-
公开(公告)号：US20220111094A1
公开(公告)日：2022-04-14
申请号：US17500908
申请日：2021-10-13
Applicant: Trevor Percival Castor
Inventor： Trevor Percival Castor
Abstract: The present invention is directed to methods and apparatus for pathogen decontamination of personal protective equipment (PPE), face filtering respiratory devices (FFR) and single use medical devices (SUD) by supercritical fluids, near critical fluids, and critical fluids with or without polar cosolvents. The invention includes a closed processing chamber for containing and processing the PPE, FFR, and SUD by a supercritical fluid, near critical fluid, and critical fluid with or without polar solvents at a specified temperature and pressure for a specified time sufficient to disrupt or inactivate pathogens and viruses on the PPE, FFR, and SUD without damaging the protective equipment so that they may be revitalized for continued use.
-
公开(公告)号：US20200093742A1
公开(公告)日：2020-03-26
申请号：US16698382
申请日：2019-11-27
Applicant: Trevor Percival Castor
Inventor： Trevor Percival Castor
IPC: A61K9/127 , A61K31/365 , A61K31/4045 , A61P31/12 , A61K31/19 , A61K31/325 , A61K38/15 , A61K31/167 , A61K31/20 , A61K47/69 , A61K47/68
Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.
-
公开(公告)号：US08629177B2
公开(公告)日：2014-01-14
申请号：US13216077
申请日：2011-08-23
Applicant: Trevor Percival Castor , Geoffrey Purdum
Inventor： Trevor Percival Castor , Geoffrey Purdum
CPC classification number: A61K31/352 , A61K9/4858 , A61K9/5153 , A61K9/5192 , B82Y5/00
Abstract: Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids as a therapeutic. One embodiment of the present invention directed to the article of manufacture comprises a lyophilized particle or sphere having a diameter of about 100 to 500 nanometers having a shell and comprising a biodegradable polymer containing a cannabinoid. A featured cannabinoid is delta-9-tetrahydrocannabinol (delta-9-THC).
Abstract translation: 本发明的实施方案涉及制造这些制品的制造方法和用于将大麻素作为治疗剂递送的用途的方法。 涉及制品的本发明的一个实施方案包括直径为约100至500纳米的具有外壳并包含含有大麻素的生物可降解聚合物的冻干颗粒或球体。 特征大麻素是δ-9-四氢大麻酚（δ-9-THC）。
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.019 seconds)
